In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver

Journal of Pharmaceutical Sciences

Volumn 96, Issue 2, 2007, Pages 428-437

  Katoh, Miki ^a   Sawada, Toshiro ^a   Soeno, Yoshinori ^b   Nakajima, Miki ^a   Tateno, Chise ^c   Yoshizato, Katsutoshi ^c,d   Yokoi, Tsuyoshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b PhoenixBio USA Corporation   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Cytochrome P450 2D6; Debrisoquin 4 hydroxylation; Humanization; in vivo model; Inhibition; Pharmacokinetic; Quinidine

Indexed keywords

4' HYDROXYDEBRISOQUIN; CYTOCHROME P450; CYTOCHROME P450 2D6; DEBRISOQUINE; DRUG METABOLITE; HUMAN ALBUMIN; PAROXETINE; QUINIDINE; UNCLASSIFIED DRUG; UROKINASE;

ALBUMIN BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CHIMERA; CONCENTRATION (PARAMETERS); DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; GENOTYPE; HUMAN; HUMAN CELL; HYDROXYLATION; LIVER CELL; LIVER MICROSOME; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

EID: 33847034231     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20783     Document Type: Article

References (28)

1. Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C, Tachibana A, Soeno Y, Asahina K, Hino H, Asahara T, Yokoi T, Furukawa T, Yoshizato K. 2004. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 165:901-912.
2. Katoh M, Matsui T, Nakajima M, Tateno C, Kataoka M, Soeno Y, Horie T, Iwasaki K, Yoshizato K, Yokoi T. 2004. Expression of human cytochromes P450 in chimeric mice with humanized liver. Drug Metab Dispos 32:1402-1410.
3. Katoh M, Matsui T, Nakajima M, Tateno C, Soeno Y, Horie T, Iwasaki K, Yoshizato K, Yokoi T. 2005. In vivo induction of human cytochrome P450 enzymes expressed in chimeric mice with humanized liver. Drug Metab Dispos 33:754-763.
4. Katoh M, Matsui T, Okumura H, Nakajima M, Nishimura M, Naito S, Tateno C, Yoshizato K, Yokoi T. 2005. Expression of human phase II enzymes in chimeric mice with humanized liver. Drug Metab Dispos 33:1333-1340.
5. Katoh M, Watanabe M, Tabata T, Sato Y, Nakajima M, Nishimura M, Naito S, Tateno C, Iwasaki K, Yoshizato K, Yokoi T. 2005. In vivo induction of human cytochrome P450 3A4 by rifabutin in chimeric mice with humanized liver. Xenobiotica 35:863-875.
6. Wilkinson GR. 2005. Drug metabolism and variability among patients in drug response. N Engl J Med 352:2211-2221.
7. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
8. Ingelman-Sundberg M. 2005. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6-13.
9. Hemeryck A, Belpaire FM. 2002. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: An update. Curr Drug Metab 3:13-37.
10. Caporaso NE, Shaw GL. 1991. Clinical implications of the competitive inhibition of the debrisoquin-metabolizing isozyme by quinidine. Arch Intern Med 151:1985-1992.
11. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. 1996. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42.
12. Hiroi T, Chow T, Imaoka S, Funae Y. 2002. Catalytic specificity of CYP2D isoforms in rat and human. Drug Metab Dispos 30:970-976.
13. Dalen P, Dahl ML, Eichelbaum M, Bertilsson L, Wilkinson GR. 1999. Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes. Pharmacogenetics 9:697-706.
14. Corchero J, Granvil CP, Akiyama TE, Hayhurst GP, Pimprale S, Feigenbaum L, Idle JR, Gonzalez FJ. 2001. The CYP2D6 humanized mouse: Effect of the human CYP2D6 transgene and HNF4α on the disposition of debrisoquine in the mouse. Mol Pharmacol 60:1260-1267.
15. Yamazaki H, Shibata A, Suzuki M, Nakajima M, Shimada N, Guengerich FP, Yokoi T. 1999. Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab Dispos 27:1260-1266.
16. Nakajima M, Tane K, Nakamura S, Shimada N, Yamazaki H, Yokoi T. 2002. Evaluation of approach to predict the contribution of multiple cytochrome P450s in drug metabolism using relative activity factor: Effects of the differences in expression levels of NADPH-cytochrome P450 reductase and cytochrome b5 in the expression system and the differences in the marker activities. J Pharm Sci 91:952-963.
17. Nakajima M, Suzuki M, Yamaji R, Takashina H, Shimada N, Yamazaki H, Yokoi T. 1999. Isoform selective inhibition and inactivation of human cytochrome P450s by methylenedioxyphenyl compounds. Xenobiotica 29:1191-1202.
18. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. 1991. Debrisoquine/sparteine hydroxylation genotype and phenotype: Analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 10:545-558.
19. Dahl ML, Johansson I, Palmertz MP, Ingelman-Sundberg M, Sjoqvist F. 1992. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 51:12-17.
20. Heim M, Meyer UA. 1990. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336:529-532.
21. Johansson I, Lundqvist E, Dahl ML, Ingelman-Sundberg M. 1996. PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 6:351-355.
22. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. 1977. Polymorphic hydroxylation of debrisoquine in man. Lancet 2:584-586.
23. Masubuchi Y, Iwasa T, Hosokawa S, Suzuki T, Horie T, Imaoka S, Funae Y, Narimatsu S. 1997. Selective deficiency of debrisoquine 4-hydroxylase activity in mouse liver microsomes. J Pharmacol Exp Ther 282:1435-1441.
24. Allen JG, East PB, Francis RJ, Haigh JL. 1975. Metabolism of debrisoquine sulfate. Identification of some urinary metabolites in rat and man. Drug Metab Dispos 3:332-337.
25. Granvil CP, Krausz KW, Gelboin HV, Idle JR, Gonzalez FJ. 2002. 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine. J Pharmacol Exp Ther 301:1025-1032.
26. Schweikl H, Taylor JA, Kitareewan S, Linko P, Nagorney D, Goldstein JA. 1993. Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics 3:239-249.
27. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. 2006. The human intestinal cytochrome P450 "PIE". Drug Metab Dispos 34:880-886.
28. Bertelsen KM, Venkatakrishnan K, von Moltke LL, Obach RS, Greenblatt DJ. 2003. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: Comparison with fluoxetine and quinidine. Drug Metab Dispos 31:289-293.